Discontinuation report ALIMTA
Report ID | 136207 |
Drug Identification Number | 02253437 |
Brand name | ALIMTA |
Common or Proper name | PEMETREXED DISODIUM FOR INJECTION |
Company Name | ELI LILLY CANADA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | PEMETREXED |
Strength(s) | 500MG |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 500mg /50mL vial |
ATC code | L01BA |
ATC description | ANTIMETABOLITES |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2021-09-17 |
Actual discontinuation date | 2021-09-17 |
Remaining supply date | 2021-09-17 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | ALIMTA® 500mg /50mL (DIN 02253437) has been discontinued. The ALIMTA 100mg /10mL vial (DIN 02306433) remains available. |
Company comments | Please contact Eli Lilly Canada's Response Centre 1-888-545-5972 should you have any questions. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | EXCHANGE TOWER, 130 KING STREET WEST TORONTO, ONTARIO CANADA M5X 1B1 |
Company contact information | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v9 | 2021-09-18 | English | Compare |
v8 | 2021-09-17 | French | Compare |
v7 | 2021-09-17 | English | Compare |
v6 | 2021-09-17 | English | Compare |
v5 | 2021-09-01 | French | Compare |
v4 | 2021-09-01 | English | Compare |
v3 | 2021-03-24 | French | Compare |
v2 | 2021-03-24 | English | Compare |
v1 | 2021-03-24 | English | Compare |
Showing 1 to 9 of 9